WO2014046481A1 - 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 - Google Patents
세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 Download PDFInfo
- Publication number
- WO2014046481A1 WO2014046481A1 PCT/KR2013/008445 KR2013008445W WO2014046481A1 WO 2014046481 A1 WO2014046481 A1 WO 2014046481A1 KR 2013008445 W KR2013008445 W KR 2013008445W WO 2014046481 A1 WO2014046481 A1 WO 2014046481A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- seq
- active ingredient
- conjugate
- cell
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title claims abstract description 40
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 219
- 239000004480 active ingredient Substances 0.000 claims abstract description 61
- 239000012634 fragment Substances 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 124
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 60
- 239000002872 contrast media Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 239000013598 vector Substances 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 13
- 230000003834 intracellular effect Effects 0.000 claims description 11
- 210000003470 mitochondria Anatomy 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000035699 permeability Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- -1 ferrocene carboxylate Chemical class 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000005090 green fluorescent protein Substances 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- 150000008163 sugars Chemical class 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 229960000074 biopharmaceutical Drugs 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 38
- 229940024606 amino acid Drugs 0.000 description 36
- 239000000562 conjugate Substances 0.000 description 35
- 108020001507 fusion proteins Proteins 0.000 description 20
- 102000037865 fusion proteins Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000002438 mitochondrial effect Effects 0.000 description 16
- 241000282414 Homo sapiens Species 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 229930182555 Penicillin Natural products 0.000 description 9
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 9
- 229940049954 penicillin Drugs 0.000 description 9
- 229960005322 streptomycin Drugs 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000007547 defect Effects 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 239000007758 minimum essential medium Substances 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 238000004624 confocal microscopy Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 208000013824 Acidemia Diseases 0.000 description 6
- 208000010444 Acidosis Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 5
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 5
- 108010017842 Telomerase Proteins 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 235000003642 hunger Nutrition 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 108091035539 telomere Proteins 0.000 description 5
- 210000003411 telomere Anatomy 0.000 description 5
- 102000055501 telomere Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 108020005196 Mitochondrial DNA Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000019932 Aciduria Diseases 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical class N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 description 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- HBBSDZXXUIHKJE-UHFFFAOYSA-N 6-hydrazinylpyridine-3-carboxylic acid Chemical compound NNC1=CC=C(C(O)=O)C=N1 HBBSDZXXUIHKJE-UHFFFAOYSA-N 0.000 description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000002033 Myoclonus Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 201000007981 Reye syndrome Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 description 1
- BZCXOYQIXRGIML-UHFFFAOYSA-N 1,3,7,10-tetrazacyclotetradecane Chemical compound C1CCNCNCCCNCCNC1 BZCXOYQIXRGIML-UHFFFAOYSA-N 0.000 description 1
- ITWBWJFEJCHKSN-UHFFFAOYSA-N 1,4,7-triazonane Chemical compound C1CNCCNCCN1 ITWBWJFEJCHKSN-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 101100162210 Aspergillus parasiticus (strain ATCC 56775 / NRRL 5862 / SRRC 143 / SU-1) aflM gene Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100102500 Caenorhabditis elegans ver-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 1
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 229910052691 Erbium Inorganic materials 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000035177 MELAS Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000035155 Mitochondrial DNA-associated Leigh syndrome Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000013234 Pearson syndrome Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101100240886 Rattus norvegicus Nptx2 gene Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 1
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108091060271 Small temporal RNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 101710195626 Transcriptional activator protein Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000010399 Wasting Syndrome Diseases 0.000 description 1
- 201000010802 Wolfram syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 206010062937 cyclic vomiting syndrome Diseases 0.000 description 1
- GPRSOIDYHMXAGW-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopentanecarboxylic acid iron Chemical compound [CH-]1[CH-][CH-][C-]([CH-]1)C(=O)O.[CH-]1C=CC=C1.[Fe] GPRSOIDYHMXAGW-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 1
- UYFPKVFXUSSLHS-UHFFFAOYSA-N ethene gadolinium Chemical group [Gd].C=C.C=C UYFPKVFXUSSLHS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- IZOOGPBRAOKZFK-UHFFFAOYSA-K gadopentetate Chemical compound [Gd+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O IZOOGPBRAOKZFK-UHFFFAOYSA-K 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000012461 inherited thrombocytopenia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000003531 maternally-inherited Leigh syndrome Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 108010007425 oligomycin sensitivity conferring protein Proteins 0.000 description 1
- 150000005527 organic iodine compounds Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 108010004034 stable plasma protein solution Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
Definitions
- the present specification relates to a cell-penetrating peptide derived from telomerase, a conjugate of the cell-penetrating peptide and an active ingredient, and a supernatant including the conjugate.
- nucleic acid proteins or nanoparticles have great potential as therapeutic materials at the molecular level, but their use is limited to tissue penetration and cell membrane resistance.
- the development of systems that can transport these substances into cells has been a hot topic in the treatment of molecular methods.
- intracellular transport is possible by various reagents, electroporation, or heat shock, etc., but in the case of proteins, they move into cells while maintaining their activity. It was a very difficult problem to get a clue to the solution.
- HIV-TAT protein consisting of 11 amino acid sequences, was found to play an important role in the cellular process of transfection of HIV cells. The study was conducted.
- Telomere is a genetic material repeatedly present at the end of a chromosome and is known to prevent damage to the chromosome or binding to another chromosome. Each time a cell divides, the telomeres get slightly shorter. After a certain number of cell divisions, the telomeres become very short, and the cells stop dividing and die. On the other hand, elongation of telomeres is known to prolong cell life. For example, cancer cells secrete telomerase, which prevents telomeres from shortening, so cancer cells can continue to proliferate without dying. .
- One aspect of the invention is to provide a novel peptide. .
- One aspect of the invention is to provide a polynucleotide encoding a novel peptide.
- One aspect of the invention is to provide a cell permeable peptide.
- One aspect of the present invention is to provide a peptide useful as an intracellular active ingredient carrier.
- Another aspect of the present invention is to provide useful peptides for intracellular effective ingredient delivery, in particular for topical delivery to mitochondria.
- Another aspect of the present invention is to provide a useful peptide for topically delivering to the mitochondria an active ingredient for ameliorating, preventing or treating mitochondrial-related diseases or disorders.
- One aspect of the present invention is to provide a conjugate conjugated with the cell-penetrating peptide and the active ingredient (conjugated).
- One aspect of the present invention is to provide a composition comprising a conjugate of a cell-penetrating peptide and an active ingredient.
- One aspect of the present invention is to provide a pharmaceutical composition comprising a conjugate of a cell-penetrating peptide and an active ingredient.
- One aspect of the present invention is to provide a functional cosmetic composition comprising a conjugate of the cell-penetrating peptide and the active ingredient.
- One aspect of the present invention is to provide a health food composition comprising a conjugate of a cell-penetrating peptide and an active ingredient.
- One aspect of the present invention is to provide a contrast agent comprising a conjugate of a cell-penetrating peptide and an active ingredient.
- the conjugate according to one aspect of the present invention is a conjugate of a cell-permeable carrier peptide and an active ingredient, wherein the carrier peptide is any one of SEQ ID NOs: 1 to 6 A peptide comprising, a peptide having at least 80% sequence homology with the depth sequence, or a fragment thereof, wherein the peptide and fragment having at least 80% sequence homology refer to one of SEQ ID NOs: 1 to 6 A conjugate that retains the cellular permeability of the peptide.
- the fragment may be a fragment consisting of three or more amino acids.
- the carrier peptide may be a peptide composed of up to 30 amino acids.
- the carrier peptide is SEQ ID NO:
- the contrast agent according to one aspect of the present invention may be a contrast agent including any one of the conjugates mentioned above.
- the contrast material may be for contrasting the cells.
- the cell may be a stem cell.
- composition according to one aspect of the invention may comprise any of the conjugates mentioned above.
- the active ingredient is an active ingredient for the treatment or prevention of a disease
- the composition may be a pharmaceutical composition.
- the active ingredient is an active ingredient of a functional cosmetic
- the composition may be a cosmetic composition.
- the active ingredient is an active ingredient of a functional health food, and the composition may be a health food composition.
- a method according to an aspect of the present invention is a method for delivering an active ingredient into a cell, comprising administering any one of the above-mentioned conjugates to a subject in need thereof.
- the carrier peptide is a cell-penetrating peptide that performs intracellular delivery of the active ingredient, and peptides and fragments having 80% or more of sequence homology are those of one of SEQ ID NOs: 1 to 6 It may have cell permeability.
- a method for delivering an active ingredient into a cell may be to locally deliver the active ingredient to the intracellular mitochondria.
- the polynucleotide according to one aspect of the present invention may be a polynucleotide encoding the above-mentioned cell permeable peptide.
- the vector according to an aspect of the present invention may be a vector including the polynucleotide.
- the transformed cell according to an aspect of the present invention may be a transformed cell comprising the vector.
- peptides disclosed herein or conjugates in which the peptide and the active ingredient are bound
- the acid it is possible to easily transfer into the cell active ingredients that are difficult to penetrate into the cell. Through this, the efficacy of the active ingredient can be increased, and as a result, the dosage can be lowered, thereby minimizing side effects due to drug administration and increasing the treatment efficiency.
- local delivery to mitochondria can enhance the effectiveness of the improvement, prevention or treatment of mitochondrial-related diseases or disorders.
- even a very small amount of active ingredients can produce excellent effects.
- Conjugation with a contrast agent can be used as a contrast agent to monitor cell transplantation processes or transplanted cells in cell therapy. In particular, it can be effectively used as a contrast agent for stem cells injected in vivo.
- FIG. 1 is a diagram illustrating a method for preparing a recombinant DNA clone in which peptides of SEQ ID NO: 1 to SEQ ID NO: 6 are bound to enhanced reporter genes (enhanced green fluorescent protein, EGFP) It is.
- enhanced reporter genes enhanced green fluorescent protein, EGFP
- 2 to 7 are diagrams showing the number of cells taken up by binding the FITC to the peptide of SEQ ID NO: 1 to SEQ ID NO: 6 and then treated in HeLa cell line and analyzed by flow cytometry.
- the control group was treated only with FITC.
- the cells were treated with Huh7 cell lines and analyzed by flow cytometry.
- the control group was treated only with FITC.
- each human T lymphocyte cell line was treated and analyzed by flow cytometry.
- the control group was treated with FITC only.
- 16 to 21 show the results of measuring cell viability and toxicity after binding FITC to peptides of SEQ ID NO: 1 to SEQ ID NO: 6, treating each of the HeLa cell lines, and culturing.
- Proteins, nucleic acids, peptides or viruses have great potential as therapeutic substances. However, due to its molecular size, its use was limited because it could not penetrate tissues and cell membranes. In addition, even small-sized substances do not penetrate the lipid bilayer of the cell membrane due to their properties and structure. Electricity
- the transcriptional activator protein is known to act as a cell penetrating peptide capable of transporting large active substances into cells. Studies have been actively conducted. In particular, unlike TAT proteins, which are known to cause intracellular toxicity, studies on substances capable of more effectively transferring large molecules such as proteins, nucleic acids, peptides or viruses into target cells without causing toxicity in vivo Proceeded. Thus, through continuous studies, the inventors have found that peptides derived from telomerase have excellent effects as cell-permeable peptides with little cytotoxicity.
- telomerase 8 is the sequence of human telomerase full-length protein.
- the "name” in Table 1 below is to distinguish peptides.
- at least one of the peptides set forth in SEQ ID NO: 1 to SEQ ID NO: 6 includes a "synthetic peptide" synthesized by selecting a peptide at a corresponding position among peptides contained in telomerase.
- the term “pep” refers to a peptide having any sequence of SEQ ID NO: 1 to SEQ ID NO: 6, or a peptide having 80% or more sequence homology with the sequence, or a fragment of the sequence.
- One aspect of the present invention provides a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a peptide having a sequence homology of 80% or more with the peptide sequence, or a polynucleotide encoding a fragment thereof. do .
- the polynucleotides can be used to mass produce peptides.
- polynucleotides encoding peptides By incorporating the vector into the host cell, the peptide can be mass-produced.
- the peptides disclosed herein may include peptides having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% homology. have.
- the peptides disclosed herein, peptides or fragments thereof comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 and one or more amino acids, two or more amino acids, three or more amino acids, four or more amino acids, 5 or more amino acids, 6 or more amino acids, or 7 or more amino acids may comprise a peptide.
- the amino acid change belongs to the property to change the physicochemical properties of the teat.
- amino acid changes can be performed, such as improving the thermal stability of the peptide, altering substrate specificity, changing the optimal pH, and the like.
- amino acid includes D-isomers and modified amino acids as well as 22 standard amino acids that are naturally incorporated into peptides. Accordingly, in one aspect of the present invention, the peptide may be a peptide including D-amino acid. Meanwhile, in another aspect of the present invention, the peptide may include a non-standard amino acid or the like which has been post-translational modified. Examples of post-translational modifications include phosphorylation, glycosylat ion, acylation (eg, acetylation, myristoylat ion and
- Palmitoylation alkylat ions
- chemical properties e.g., beta-elimination deimidization, Deamidation
- structural changes e.g, formation of disulfide bridges
- Changes in amino acids such as changes in amino acids, such as amino groups, carboxyl groups or side chains, caused by chemical reactions occurring in the process of bonding with crossl inkers.
- Peptides disclosed herein can be wild-type peptides identified and isolated from native sources.
- the peptides disclosed herein may be artificial variants in which one or more amino acids comprise an amino acid sequence in which one or more amino acids are substituted and / or inserted compared to the peptides of any one of SEQ ID NOs: 1-6.
- Amino acid changes in the wild type polypeptide as well as in artificial variants include conservative amino acid substitutions that do not significantly affect the folding and / or activity of the protein. Examples of conservative substitutions include basic amino acids (arginine, lysine and histidine), Acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and
- hydrophobic amino acids leucine, isoleucine, valine and methionine
- aromatic amino acids phenylalanine, tryptophan and tyrosine
- small amino acids glycine, alanine, serine and threonine
- the most common exchanges are Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Tyr / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, and Asp / Gly, and vice versa.
- Other examples of conservative substitutions are shown in the following table.
- hydrophobic norleucine, met ⁇ ala, val, leu, ile
- Non-conservative substitutions will be made by exchanging a member of one of these classes for another class. Any cysteine residue that is not involved in maintaining the proper conformation of the peptide can generally be substituted with serine to improve the oxidative stability of the molecule and to prevent abnormal crosslinking. Conversely, cysteine bond (s) can be added to the peptide to improve its stability.
- Another type of amino acid variant of the peptide is a change in the glycosylation pattern of the antibody.
- change is meant the deletion of one or more carbohydrate residues found in the peptide and / or the addition of one or more glycosylation sites that are not present in the peptide.
- Glycosylation of peptides is typically either N-linked or 0-linked, wherein an N-linked carbohydrate residue is attached to the side chain of an asparagine residue.
- Tripeptide sequences asparagine—X-serine and asparagine-X-threonine, where X is any amino acid except proline, are recognition sequences for enzymatic attachment of carbohydrate moieties to the asparagine side chains.
- X is any amino acid except proline
- 0-linked glycosylation means attaching one of the sugars N-acetyl galactosamine, galactose or xylose to hydroxyamino acid, most commonly serine or threonine, but not 5-hydroxyproline or 5-hydroxy Roxylysine can also be used.
- glycosylation sites to the peptide is conveniently performed by changing the amino acid sequence to contain one or more of the above mentioned tripeptide sequences (for N-linked glycosylation sites). Such changes may be made by adding one or more serine or threonine residues to the sequence of the original antibody or by substituting these residues (for a 0-linked glycosylation site).
- One aspect of the present invention provides a cell permeable peptide comprising a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6, or fragments thereof, or a peptide or Peptides having at least 80% sequence homology are provided.
- One aspect of the present invention provides a drug carrier for delivering one or more active ingredients, a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof, or a sequence homology of 80% or more with the peptide sequence. It provides a pharmaceutical composition comprising a peptide having.
- a peptide comprising any one of SEQ ID NOs: 1 to 6, or a fragment thereof, or a peptide having a sequence homology of 803 ⁇ 4> or more with the peptide sequence may act as a safe and excellent cell permeable peptide. In combination with the drug can effectively deliver into the cell.
- a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6, or a fragment thereof, or a peptide having 80% or more sequence homology with the peptide sequence and an active ingredient to be moved are conjugated to each other.
- the active ingredient may be one or more selected from protein, nucleic acid, peptide lipids, glycolipids, minerals, sugars, contrast materials, drugs (compounds) and chemicals (compounds).
- the active ingredient may be a peptide.
- the peptide as an active ingredient may be a cytokine, an antibody, an antibody fragment, a therapeutic enzyme, a soluble receptor, or a ligand.
- CPP Cell Penetrating Peptide
- the term “cargo” includes any substance that can move into a cell in combination with a cell permeable template, for example, any substance that wants to increase cell permeation efficiency, specifically, Active substances in drugs, cosmetics or healthy foods, more specifically substances that are not easily transported into the cell through the general route, and more specifically sugars, nanoparticles such as proteins, nucleic acids, peptides, minerals and glucose Or, but not limited to, biologicals, viruses, contrasts or other chemicals. It is a broad concept including a relief, preventing, treating or substance for diagnosis.
- carrier peptide refers to a peptide that serves to move an active ingredient to a desired site by binding to an active ingredient.
- the protein or peptide to be moved includes one or more of hormones, hormone analogs, enzymes, enzyme inhibitors, signal transduction proteins (or peptides), antibodies and vaccines, including but not limited to no.
- the nucleus Acids may be naturally occurring or artificial DNA or RNA molecules and may be single stranded or double stranded.
- the nucleic acid molecule may be more than one, and may be nucleic acid molecules of the same type (eg, having the same nucleotide sequence), or may be other types of nucleic acid molecules.
- the virus may comprise a viral core comprising the entire virus or a nucleic acid of the virus.
- chemicals are broad concepts, including chemicals that can function as drugs, and include natural or synthetic chemicals.
- the drug delivered into the cell by the cell-penetrating peptide may further comprise a drug carrier such as liposomes, micelles, nanoparticles, magnetic particles, or tubular dots.
- contrast 1 is a broad concept that includes all materials used for the imaging of structures or fluids in vivo in medical imaging.
- Suitable contrast agents are radiopaque contrast media ( radiopaque contrast agents, paramagnetic contrast agents, superparamagnetic contrast agents, computed tomography (CT) contrast agents and other contrast agents, including but not limited to Radiopaque contrast agents (for X-ray imaging) include inorganic iodine compounds and organic iodine compounds (e.g., diatrizoat), radiopaque metals and their salts (e.g.
- radiopaque compounds eg, calcium salts, barium salts such as barium sulfate, tantalum and tantalum oxide.
- Gd-DTPA gadolinium diethylene triamine penta acetic acid
- Gd-DTPA gadolinium di ethylene tr iaminepentaacet ic acid
- Euopium, erbium, crumb, nickel and cobalt complexes for example 1,4,7, 10-tetraazacyclododecane-N, N ', N ", N"' Tetraacetic acid (D0TA), Ethylenediamintetraacetic acid (EDTA), 1,4,7,10-tetraazacyclododecane-N, -N ', ⁇ "-triacetic acid (D03A), 1,4,7 -Triazacyclononane — ⁇ , ⁇ "-triacetic acid (N0TA), 1,4,8,10-tetraazacyclotetradecane ', ⁇ ", ⁇ ' ⁇ tetrateacetic acid ( ⁇ ), hydroxydoxybenzyl Ethylene ⁇ diamine diacetic acid (HBED), etc.
- Suitable superparamagnetics for example 1,4,7, 10-tetraazacyclododecane-N, N ', N ", N"' Tetraacetic acid (
- Contrast material for MR imaging is magnetite, superparamagnetic iron oxide iron oxide (SPIO), ultraparamagnetic iron oxide (USPIO) and monocrystalline iron oxide (monocrystai line).
- SPIO superparamagnetic iron oxide iron oxide
- USPIO ultraparamagnetic iron oxide
- monocrystalline iron oxide monocrystai line
- Other suitable contrast agents may be contrast agents such as iodide and non-iodinated, ionic and nonionic CT contrast agents, and spin-labels, or other diagnostics.
- contrast agents include, but are not limited to, ⁇ -galactosidase, green fluorescent protein, blue fluorescent protein, luciferase, and the like, which encode proteins that are readily detectable when expressed in cells. Marker genes.
- Various labels can be used, such as radionuclides, fluorescents, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, ligands (especially hapten), and the like.
- the contrast material is of the formula (2)
- Ferrocenecarboxylic acid The structure of ferrocene is shown in Formula 1.
- the conjugate of the cell-penetrating peptide and the contrast material may be Ferrocenecarboxylic -pep (Ferrocenecarboxylic-pep) of the formula (3). ⁇ 75> [Formula 3]
- the peptide or composition may be one or more detectable
- the label can be a compound that can be detected chemically, physically, or enzymatically or directly or indirectly to generate a signal. Labeling and subsequent detection can be performed by methods known in the art (eg, Sambrook, J., and Russel, DW (2001); and Lottspeich, F., and Zorbas H. (1998) Bioanalyt) ik, Spektrum Akademischer Ver 1 ag, Heidelberg / Berlin,
- Labels include, but are not limited to, fluorescent labels, enzyme labels, chromogenic labels, luminescent labels, radiolabeled hapten, biotin, metal complexes, metals and colloidal gold. All these types of labels are well known in the art and are commercially available from various suppliers.
- binding methods such as covalent or non-covalent bonds.
- the subject to be moved may, for example, bind to the N-terminus or C-terminus of the peptide according to one aspect of the invention.
- a peptide may be used via a disulfide bond or a covalent bond that binds the moving object to an alpha amine ( ⁇ -amine) or C-terminal lysine (K) residue of the peptide N-terminal glutamate (E). You can combine the moving target.
- one of the peptides and the moving object may be bound to the peptide and the moving object through a non-covalent bond that surrounds the other in a form such as a capsular form.
- a linker may be used to associate a peptide with a moving object.
- a hyal (6—hydrazinopyridine-3-carboxylic acid, 6-hydrazinopyridine-3-carboxylic acid) linker may be used for the alpha amine of the peptide N-terminal glutamate or the amine of the C-terminal lysine residue.
- the moving object can be bound to the peptide by binding the moving object to the linker.
- the peptide when the moving target is DNA or RA, the peptide is introduced with a SH group (thiol group) and the DNA or RNA with a maleimide group and then a peptide.
- SH group thiol group
- the transfer target By linking the SH group and DNA or RA maleimide group, the transfer target can be bound to the peptide.
- the moving target is a protein or a peptide
- the transport peptide can be coupled to the carrier peptide in the form of a fusion protein.
- Specific examples of the binding by the fusion protein are as follows: In preparing a primer for producing the fusion protein, the nucleotide encoding the carrier peptide is attached to the nucleotide expressing the moving target, followed by the obtained nucleotide. Is inserted into a vector, for example, a pET vector as a restriction enzyme, and expressed by introducing (transformation) BL-2KDE3) into, for example, a cell. At this time,
- Expression inducers such as isopropyl-l-thio- -D-galactopyranoside (IPTG), can be treated to effectively express fusion proteins. After, His tag
- fusion protein expressed through a method such as purification can be purified, and then dialyzed using PBS, and put into a kit, for example, concentrated by centrifugation for 5 to 20 minutes at 2,000 to 4,000 rpm.
- the carrier peptide is capable of binding to a dyeing or fluorescent material, specifically fluorescein isothiocyanate (FITC) or green fluorescent protein (GFP).
- FITC fluorescein isothiocyanate
- GFP green fluorescent protein
- the FTTC may bind to the amino group (N3 ⁇ 4 + ) of the N′-terminal or C-terminal Lys of the carrier peptide.
- the peptide and the FITC may be bound by a linker including Lys.
- a peptide comprising any one of SEQ ID NOs: 1 to 6 as disclosed herein, or a fragment thereof, or a peptide having at least 80% sequence homology with the peptide sequence may be carried.
- the molar ratio of CPP: to be moved may be 2: 1 or more. Specifically, it may be 2: 1 or more, 3: 1 or more, 4: 1 or more, 5: 1 or more, 6: 1 or more, 7: 1 or more, 8: 1 or more, 9: 1 or more, or 10: 1 or more. This means that a plurality of carrier peptides can bind to one molecule of movement.
- the plurality of carrier peptide molecules may be linked in series or in parallel with each other. Linked in series means binding to each other at the terminal amino acid sites of the carrier peptide. In parallel, linked in parallel means binding to each other at portions other than the terminal amino acids of the carrier peptide.
- the molar ratio of carrier peptide: move target can be 1: 2 or more. This means that a plurality of move target molecules can bind to one carrier peptide molecule.
- the molar ratio of the carrier peptide to the moving object may be 1: 2. Specifically, it may be 1: 2 or more, 1: 3 or more, 1: 4 or more, 1: 5 or more, 1: 6 or more, 1: 7 or more, 1: 8 or more, 1: 9 or more, or 1:10 or more. .
- the carrier peptide according to one aspect of the present invention can be used for cell imaging or tracking the intracellular drug delivery route.
- One aspect of the present invention provides a drug for delivering one or more active ingredients of a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof or a peptide having 80% or more sequence homology with the peptide sequence. It serves as a carrier.
- One aspect of the invention is a drug; And applying to a subject a cell comprising a composition comprising a peptide comprising any one of SEQ ID NOs: 1 to 6, or a fragment thereof, or a peptide having at least 80% sequence homology with the peptide sequence.
- a method of delivering a drug is provided.
- a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof, or a peptide having a sequence homology of 80% or more with the peptide sequence, and a contrast agent to the subject.
- a method for tracking the route of application drug delivery to a subject comprising application is provided.
- a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof or a conjugate of a peptide and a contrast material having a sequence homology of 80% or more with the peptide sequence
- a method for tracking the route of application drug delivery to a subject including application to the subject.
- One aspect of the present invention provides a conjugate comprising a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof or a peptide having a sequence homology of 80% or more with the peptide sequence and a conjugate of a drug to be moved.
- a composition comprising; And a kit for intracellular drug delivery to a subject, including instructions indicative of one or more of the dosage, route of administration, frequency of administration, and redness.
- One aspect of the present invention is an active ingredient; And a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or fragments thereof, or 80% of the peptide sequence.
- a cosmetic or food composition comprising a peptide having sequence homology to a phase is provided.
- Another aspect of the present invention comprises a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof, or a conjugate of an active ingredient with a peptide having at least 80% sequence homology with the peptide sequence.
- One aspect of the present invention provides a conjugate of an active ingredient with a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a fragment thereof, or a peptide having 80% or more sequence homology with the peptide sequence. Including, it provides a pharmaceutical, cosmetic or food composition excellent effect of delivering the active ingredient into the cell.
- Mitochondria are the central organs of energy metabolism in nucleated cells and are the first intracellular organs to be associated with human disease (Luft R, Ikkos D, Palmieri G, Ernster L, Afzel ius B: A case of severe hypermetabol i).
- sm of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control a correlated clinical, biochemical, and morphological study, J CI in Invest 41: 1776 804, 1962).
- the organ is also involved in the regulation of intracellular calcium concentrations, and the mitoconcrete respiratory chain acts as an important electron transport system for energy production and can cause the production of free radicals.
- mitochondrial dysfunction is closely related to adult diseases such as diabetes, cardiomyopathy, infertility, blindness, kidney / liver disease and stroke (Modica-Napolitano KS, Singh KK: April mitochondria as targets for detect ion and treatment of cancer Expert Rev Mol Med 11: 1-19, 2002).
- the mutation of the mitochondrial gene has been suggested to be involved in the invention of aging, neurodegenerative diseases, cancer diseases.
- a mitochondrial targeting active ingredient delivery system may be provided.
- the transport peptide is a peptide that performs local mitochondrial local delivery of the active ingredient as a peptide that migrates locally to the mitochondria in the cell, the sequence homology of> 803 ⁇ 4> Peptides and fragments having a mitochondrial targeting active ingredient delivery system, which possesses the mitochondrial targeting ability of one of SEQ ID NO: 1 to SEQ ID NO: 6 corresponding thereto.
- compositions for controlling mitochondrial activity And a conjugate of any one of the above-mentioned conjugates, wherein the carrier peptide is a peptide that locally migrates into the mitochondria in the cell and is a peptide that performs mitochondrial local delivery of the active ingredient.
- Peptides and fragments having more than 80% sequence homology may be a composition for controlling mitochondrial activity, having the mitochondrial targeting ability of one of the corresponding SEQ ID NO: 1 to SEQ ID NO: 6.
- the composition is a pharmaceutical composition for the treatment, prevention, inhibition of progression, or alleviation of symptoms of mitochondrial-related diseases or disorders. It may be a component that shows the function of treating, preventing, inhibiting progression or alleviating symptoms of a disease or disorder.
- Mitochondrial related diseases may include, but are not limited to: Huntington's disease; sclerosis on the muscular atrophy side; MELAS
- MERRF Myoclonus, epilepsy, and myopathy with ragged red fibers, epilepsy and myopathy of myoclonus with segmented red fibers
- NARP / MILS Neuroogenic muscular weakness, ataxia, retinitis pigmentosa / Maternal ly inherited Leigh syndrome, neuromuscular weakness, ataxia and pigmented retinitis / maternal hereditary Reye syndrome
- LHON Lebers hereditary optic neuropathy, lever's hereditary optic neuropathy, mitochondrial blindness
- KSS Kearns-Sayre Syndrome
- PMPS Pearson Marrow-Pancreas Syndrome, Pearson Bone Marrow-Pancreas Syndrome
- the present invention provides a nucleic acid molecule encoding the polypeptide.
- Nucleic acid molecules can be introduced into host cells according to techniques known to those of skill in the art. For example, GM GCG CGC CCG GCG CTG CTG ATG AGC CGC CTG CGC ⁇ ATT CCG AAA sequence (SEQ ID NO: 181). Nucleic acid molecules can be introduced into host cells according to techniques known to those of skill in the art. For example,
- the host cell may be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or a prokaryotic cell, such as a bacterial cell.
- Prokaryotic strains suitable for transformation include species belonging to the genus Escherichia coli, Bacillus subtilis, Salmonella typhimurium, Pseudomonas, Strap Thomas and Micbacteria.
- Vectors comprising such nucleic acid molecules generally have a replication origin and selectable markers (e.g., dihydrofolate reductase or neomycin resistance for eukaryotic cell culture) that allow for the transformation of host cells with recombinant expression vectors. Or tetracycline or ampicillin resistance in E. coli, or S. cerevisiae TRP1 gene), and promoters that regulate transcription of protein coating sequences.
- selectable markers e.g., dihydrofolate reductase or neomycin resistance for eukaryotic cell culture
- selectable markers e.g., dihydrofolate reductase or neomycin resistance for eukaryotic cell culture
- promoters that regulate transcription of protein coating sequences.
- Useful expression vectors that can be used are known derivatives such as, for example, SV40 and pcDNA and col El, pCRl, pBR322, pMal-C2, pET, pGEX (Smith, et al., Gene 67: 31-40 (1988))
- Phage DNA such as bacteria pollasmid, pMB9 and its derivative RP4, phage DNA such as numerous derivatives of phage I such as M989, and phage DNA such as M13 and filamentary single-stranded phage DNA;
- Yeast plasmids such as vectors derived from a combination of phage DNA and phage DNA modified for use with phage DNA or expression control sequences.
- Mammalian expression vectors include origins of replication, suitable promoters and enhancers. It may also include essential ribosomal binding sites, polyadenylation sites, splice donor and acceptor sites, transcription termination sequences, and 5 'plumtanking non-transcription sequences. Mammalian expression vectors include inducible promoters, such as those comprising dihydrofolate reductase promoters, Any expression vector containing a DHFR expression cassette or a DHFR / methotrexate co-amplification vector such as pED (Randal J, Kaufman, 1991, Randal J. Kaufman, Current
- GABA glutamine synthetase / methionine sulfoximine co-amplification vector
- pEE14 Celltech
- Vectors that direct episomal expression under the control of Epstein virus (EBV) or nuclear antigen (EBNA), such as pREP4 (Invi trogen), pCEP4 (Invi trogen), pMEP4 (Invi trogen), pREP8 (Invi trogen), pREP9 (Invitrogen), and pEBVHis (Invi trogen) can be used.
- Selective mammalian expression vectors include Rc / CMV (Invi trogen) and pRc / RSV (Invi trogen).
- Vaccinia virus mammalian expression vectors that can be used in the present invention include pSCll, pMJ601, pTKgptFIS and the like.
- Yeast expression systems that can be used in the present invention include non-fusion pYES2.
- the vector can be introduced into a variety of cellular mammals, in particular human-derived cells, as well as bacteria, yeasts, fungi, insects, lamina and plant cells.
- suitable cells include VER0. Cells, HELA cells such as ATCC No. CCL2, CH0 cell lines such as ATCC No.
- COS cells such as COS-7 cells and ATCC No. CRL 1650 cells, W138, BHK, HepG2, 3T3 such as ATCC No. CRL6361, A549, PC12, K562 cells, 293 cells, Sf9 cells, such as ATCC No. CRL1711 and Cvl cells such as ATCC No. CCL70, etc.
- suitable cells include genus of prokaryotic host cell strains, such as E. coli (such as DH5-a strain), Bacillus subtilis, Salmonella typhimurium, or Pseudomonas, Streptomyces and Staphylococcus. There are strains that belong.
- the composition according to one aspect of the present invention is a peptide comprising any one of SEQ ID NO: 1 to SEQ ID NO: 6 or a peptide thereof or 0.1 to 1 mg / mg peptide having a sequence homology of 80% or more of the peptide sequence
- the content may be included in an amount of 1; zg / rag to 0.5 mg / iiig, more specifically 10; zg / mg to 0.1 mg / mg.
- When included in the above range is not only suitable for showing the intended effect of the present invention, but also satisfies both the stability and safety of the composition, it may be appropriate to include in the above range in terms of cost-effectiveness.
- composition according to one aspect of the present invention can be applied to all animals including humans, dogs, chickens, pigs, cows, sheep, guinea pigs or monkeys.
- compositions according to one aspect of the present invention may be administered orally, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, intradural or subcutaneous.
- Formulations for oral administration include tablets, pills, soft or hard capsules, granules,
- Formulations for parenteral administration may be, but are not limited to, injections, drops, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches or sprays.
- the pharmaceutical composition according to one aspect of the present invention may include additives such as diluents, excipients, lubricants, binders, disintegrants, laxatives, dispersants, surfactants, colorants, flavoring or sweetening agents as necessary.
- additives such as diluents, excipients, lubricants, binders, disintegrants, laxatives, dispersants, surfactants, colorants, flavoring or sweetening agents as necessary.
- Pharmaceutical compositions according to one aspect of the invention may be prepared by conventional methods in the art.
- the active ingredient of the pharmaceutical composition according to one aspect of the present invention will vary depending on the age, sex, weight, pathology and severity of the subject to be administered, the route of administration, or the judgment of the prescriber. Dosage determination based on these factors is within the level of those skilled in the art and
- the daily dose may be for example 0.1 zg / kg / day to 1 g / kg / day, specifically 1 / / kg / day to 10 mg / kg / day, more specifically 10 zg / kg / day to 1 mg / kg / day, more specifically, may be 50 1 ⁇ 2 / kg / day to 100 / kg / day, but is not limited thereto.
- the pharmaceutical composition according to one aspect of the present invention may be administered once to three times a day, but is not limited thereto.
- Cosmetic compositions according to one aspect of the invention may be provided in all formulations suitable for topical application.
- it may be provided in the form of an emulsion obtained by dispersing an oil phase in a solution, an aqueous phase, an emulsion obtained by dispersing an aqueous phase in an oil phase, a suspension, a solid, a gel, a powder paste, a foam, or an aerosol.
- Such formulations may be prepared according to conventional methods in the art.
- the cosmetic composition according to one aspect of the present invention may include other ingredients that may give a synergistic effect to the main effect, preferably within a range that does not impair the main effect.
- the cosmetic composition according to an aspect of the present invention is a moisturizer, an emulsifier, a surfactant, a ultraviolet absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, an organic or inorganic pigment, a fragrance, a cooling agent or a restriction agent. It may include.
- the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount is 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the cosmetic composition Can be.
- the formulation of the food composition according to one aspect of the present invention is not particularly limited, but may be, for example, formulated into tablets, granules, powders, solutions, solid preparations, and the like. Each formulation is formulated or formulated with ingredients commonly used in the art in addition to the active ingredient. Depending on the purpose of use, those skilled in the art can select a suitable formulation without difficulty, and synergistic effects may occur when applied simultaneously with other raw materials.
- the daily dosage thereof is, for example, specifically 1 / g / kg / day to 10 mg / kg / day, more specifically 10 g / kg / day to 1 mg / kg / day, more specifically 50 zg / kg / day to 100 // g / kg / day, but is not limited thereto, and age, health of the subject to be administered It can vary depending on various factors such as condition and complications.
- Preferred embodiments of the invention include the most optimal mode known to the inventors for carrying out the invention. Variations of the preferred embodiments may become apparent to those skilled in the art upon reading the foregoing description. The inventors expect those skilled in the art to make appropriate use of such variations, and the inventors expect the invention to be practiced in a manner different from that described herein. Accordingly, the invention includes all modifications and equivalents of the subject matter referred to in the appended claims, as permitted by patent law. Moreover, any combination of the above-mentioned components within all possible variations It is included in the present invention unless expressly contradicted or clearly contradicted by context. While the invention has been particularly shown and described with reference to exemplary embodiments, those skilled in the art will appreciate that various changes in form and detail may be made without departing from the spirit and scope of the invention as defined by the following claims. .
- Peptides of SEQ ID NO: 1 to SEQ ID NO: 6 were prepared according to the solid phase peptide synthesis known in the art. Specifically, peptides were synthesized by coupling amino acids from the C-terminus one by one through Fmoc solid phase synthesis (SPPS) using ASP48S (Peptron, Inc., Daejeon, Korea). As follows, the first amino acid at the C-terminus of the peptides was attached to the resin. For example:
- a cocktail (Cleavage Cocktail) was added to separate peptides from Resin. 5) Cooling diethyl ether is added to the mixture, followed by centrifugation to precipitate the obtained peptide.
- a conjugate in which peptides of SEQ ID NO: 1 to SEQ ID NO: 6 were conjugated with FITC was prepared as follows.
- a fusion protein of a protein (enhanced green fluorescent protein, EGFP) (SEQ ID NO: 9, at least 10) is prepared by the following method.
- the pEGFP-Nl enhanced green the vector as a template, a fluorescent protein (enhanced green fluorescent protein, EGFP) in pET21a (+) vector (Novagen) for cloning and 7 i to include the hanhyo small TABLE 3
- a fluorescent protein enhanced green fluorescent protein, EGFP
- pET21a (+) vector Novagen
- EGFPF (forward) primer contains Ndel and EcoRI restriction enzyme cleavage site
- EGFP-R reverse included an Xhol restriction enzyme cleavage site and thirty EGFP sequences were added.
- KM including 5 () mM potassium chloride, 0.1% Triton X-100, ⁇ . ⁇ magnesium chloride, and 150 ⁇ of four deoxynucleotide triphosphates (dATP, dTTP, dGTP, dCTP) for gene amplification tris-HCl (tris-HCl, H 9.0) was added a primer and Taq DNA polymerase hyosoeul of 2.5U of lOOpmd to the solution and, 10ng pEGFP plasmid DNA using as a template, polymerase chain half for 5 minutes at 95 ° C in the plasmid pEGFP unggi DNA
- Ndel present in multiple cloning site (MCS) of pET21a vector
- Each F (forward) primer comprises a Ndel restriction enzyme cleavage site and is made to add a pep (CPP) DNA sequence of SEQ ID NO: 1 to SEQ ID NO: 6, each
- R (reverse) primers were constructed to include the EcoRI restriction enzyme cleavage site and to add the pep (CPP) DNA sequence of SEQ ID NO: 1 to SEQ ID NO: 6.
- the synthesized oligonucleotide product was digested with Ndel and EcoRI restriction enzymes.
- pET21a-EGFP-His tag recombinant DNA clone was cloned into Ndel and EcoRI restriction enzyme cleavage sites to prepare pET21a-pep (CPP) -EGFP-His tag recombinant DNA clone of SEQ ID NO: 1 to SEQ ID NO: 6 (Fig. One).
- the protein is isolated by transformation. Specifically, E. coli BL2KDE3) (Invitrogen, Carlsbad, CA, USA) is transformed using a 5ml LB / Empicillin medium and then cultured in 100ml medium. In this case, empicillin is added in a 50 lig / ml ratio. Then, after stirring and incubating at 37 ° C. for about 2 to 3 hours, absorbance was measured and grown to within the range of about 0.6 to 0.8, and then 0.1 mM of IPTG (Isopropyl ⁇ -D-1-thiogalactopyranoside) was used to induce the expression of the fusion protein. After treatment with ⁇ lmM and further incubated at 16 ° C ⁇ 37 ° C for 3 to 16 hours, the cells are centrifuged at 5000 rpm for 5 minutes,
- the expressed protein can be visually confirmed that the cell is overexpressed as a result of centrifugation and the cell becomes greenish. His. Remove the tag purification kit, Ni-TAT Protein Isolation Kit (Prod, # 313.14, Quiagen USA) as directed by the manufacturer.
- the protein is purified by dialysis and concentrated. Specifically dialyzed using sterile 4 ° C PBS. First equilibrate the dialysis bag with PBS, and then take the protein solution separated above using a 5 ml injector and place it in the dialysis bag, and then dialysis overnight at 4 ° C. while stirring. Then, in order to increase the concentration of protein and remove unnecessary substances, dialyzed protein was added to BIBASPIN 20 (Prod, # VS2092, Sartorius Stedin biotech, Germany) and concentrated by centrifugation at 4 ° C at 3,000 rpm.
- BIBASPIN 20 Prod, # VS2092, Sartorius Stedin biotech, Germany
- Human cervical cancer cell line (Homo sapiens cervix) from ATCC HeLa cell line, adenocarcinoma cell line, was treated with 10% fetal calf serum (Invitrogen, USA), ear le's salts, non-essential amino acids, sodium pyruvate and 100 ⁇ ⁇ / ⁇ ⁇ penicillin in MEM (Minimum Essential Medium). 100 units / mi
- Streptomycin was added and cultured in a 37t, 5% C0 2 incubator.
- the cell lines were treated with peptides of SEQ ID NOs: 1 to 6 of the present invention, pep (CPP), and flow cytometry and confocal microscopy analysis to compare the degree of control and uptake. It was.
- the cultured cell line was dispensed into chamber wells and added with 10% fetal calf serum (Invitrogen, USA), 100 iizl penicillin and 100 units / m ⁇ streptomycin to the medium at 37: 5% C0. Incubated for 12 hours in two incubators. After PBS washing, MEM (Minim ⁇
- DAPK4 ' 6-diamidino-2—phenyl indole was stained at room temperature for nuclei, and analyzed by confocal microscopy.
- Huh7 suspended cell line was used as a carcinoma cell lien.
- Huh7 cell lines use RPMI 1640 medium. 10% fetal calf serum (Invitrogen, USA), 100 ug / ml penicillin and 100 units / ml streptomycin were added to the culture medium at 37 ° C and 5% C0 2 .
- Jurkat's floating cell line was used.
- Jurkat cell lines use RPMI 1640 medium. 10% fetal calf serum (Invitrogen, USA), 100 ug / ml penicillin, 100 units / ml streptomycin was added to the culture medium at 37 ° C, 5% CO 2 incubator.
- PBMC peripheral blood mononuclear cells
- the cultured HeLa cell line was dispensed into a 96-well plate and cultured with 10% fetal bovine serum (Invitrogen, USA), 100 g / u penicillin and 100 units. Streptomycin was added and incubated for 12 hours in a 37 ° C, 5% C02 incubator. After PBS washing, MEM (Minimum Essential Medium) was subjected to starvation for 1 hour. Each carrier peptide was incubated at 20 ° C. for 24 hours, and then cell viability and toxicity were analyzed using ⁇ assay. The results are as shown in FIGS. 16 to 21.
- HeLa cell line (adenocarcinoma cell line) was treated with 10% fetal calf serum (Invitrogen, USA), Earle's salts, non-essential amino acids, sodium pyruvate and 100 / g / m ⁇ penicillin and 100 units / mi
- Streptomycin was added and incubated in a 37 ° C, 5% C0 2 incubator.
- a fusion protein is prepared by binding an enhanced green fluorescent protein (EGFP), which is a reporter gene, to peptides of SEQ ID NO: 1 to SEQ ID NO: 6 of the present invention.
- EGFP enhanced green fluorescent protein
- the cultured cell line is dispensed into chamber wells and 10% fetal calf into medium.
- Nuclei were stained at room temperature with DAPI (4 ', 6-diamidino-2-phenylindole) and analyzed by confocal microscopy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Physics & Mathematics (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020157009510A KR102201430B1 (ko) | 2012-09-19 | 2013-09-17 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
JP2015532965A JP6510410B2 (ja) | 2012-09-19 | 2013-09-17 | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 |
US14/429,641 US9631184B2 (en) | 2012-09-19 | 2013-09-17 | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
ES13839102T ES2743919T3 (es) | 2012-09-19 | 2013-09-17 | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
CN201910048425.2A CN110028554B (zh) | 2012-09-19 | 2013-09-17 | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 |
EP13839102.4A EP2899199B1 (en) | 2012-09-19 | 2013-09-17 | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
CN201910049089.3A CN110064056B (zh) | 2012-09-19 | 2013-09-17 | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 |
CN201380057722.4A CN104768967B (zh) | 2012-09-19 | 2013-09-17 | 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物 |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120104144 | 2012-09-19 | ||
KR10-2012-0104144 | 2012-09-19 | ||
KR20120109216 | 2012-09-28 | ||
KR10-2012-0109216 | 2012-09-28 | ||
KR20130017169 | 2013-02-18 | ||
KR20130017046 | 2013-02-18 | ||
KR10-2013-0017046 | 2013-02-18 | ||
KR10-2013-0017169 | 2013-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014046481A1 true WO2014046481A1 (ko) | 2014-03-27 |
Family
ID=50341702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2013/008445 WO2014046481A1 (ko) | 2012-09-19 | 2013-09-17 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9631184B2 (ko) |
EP (1) | EP2899199B1 (ko) |
JP (1) | JP6510410B2 (ko) |
KR (1) | KR102201430B1 (ko) |
CN (3) | CN110028554B (ko) |
ES (1) | ES2743919T3 (ko) |
TW (1) | TWI598441B (ko) |
WO (1) | WO2014046481A1 (ko) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540419B2 (en) | 2012-05-11 | 2017-01-10 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
EP3020724A4 (en) * | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
US9730984B2 (en) | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
US9937240B2 (en) | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
US10034922B2 (en) | 2013-11-22 | 2018-07-31 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
US10441632B2 (en) | 2016-01-29 | 2019-10-15 | Nexgen Biotechnologies, Inc. | Anti-wrinkle and anti-aging cosmetic composition comprising green fluorescent protein-human epidermal growth factor fusion protein as effective component |
US10463708B2 (en) | 2014-12-23 | 2019-11-05 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US10561703B2 (en) | 2013-06-21 | 2020-02-18 | Gemvax & Kael Co., Ltd. | Method of modulating sex hormone levels using a sex hormone secretion modulator |
US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150125438A1 (en) | 2012-07-20 | 2015-05-07 | Sang Jae Kim | Anti-Inflammatory Peptides and Composition Comprising the Same |
CN110092817B (zh) | 2012-09-19 | 2023-04-18 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
CN113699133A (zh) | 2012-09-19 | 2021-11-26 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含其的缀合物、及应用 |
CN110755599A (zh) | 2013-10-23 | 2020-02-07 | 珍白斯凯尔有限公司 | 用于治疗和预防良性前列腺增生的组合物 |
US10662223B2 (en) | 2014-04-30 | 2020-05-26 | Gemvax & Kael Co., Ltd. | Composition for organ, tissue, or cell transplantation, kit, and transplantation method |
CN107667112B (zh) | 2015-05-26 | 2021-12-07 | 珍白斯凯尔有限公司 | 新型肽和含有其的组合物 |
EP3372613A4 (en) * | 2015-11-03 | 2019-07-10 | Gemvax & Kael Co., Ltd. | PEPTIDE WITH NERVE DAMAGE PREVENTION AND REGENERATION EFFECT AND COMPOSITION THEREOF |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
US20230181681A1 (en) * | 2020-05-08 | 2023-06-15 | Industry Academic Cooperation Foundation, Hallym University | Peptide for suppressing coronavirus and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186802A1 (en) * | 2005-12-16 | 2009-07-23 | Diatos | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell |
KR20090103957A (ko) * | 2007-01-29 | 2009-10-01 | 주식회사 프로셀제약 | 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도 |
WO2010012850A1 (es) * | 2008-07-29 | 2010-02-04 | Universitat Pompeu Fabra | Péptidos con capacidad de penetración celular y sus usos |
JP2010252810A (ja) * | 1998-07-08 | 2010-11-11 | Gemvax As | テロメラーゼ由来抗原ペプチド |
WO2011150494A1 (en) * | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
KR20120026408A (ko) * | 2010-09-09 | 2012-03-19 | 서울대학교산학협력단 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6610839B1 (en) * | 1997-08-14 | 2003-08-26 | Geron Corporation | Promoter for telomerase reverse transcriptase |
JP2001523947A (ja) * | 1996-10-01 | 2001-11-27 | ジェロン コーポレイション | テロメラーゼ逆転写酵素 |
GB0112342D0 (en) * | 2001-05-21 | 2001-07-11 | Norsk Hydro As | Polypeptides |
AU2002363231A1 (en) * | 2001-10-29 | 2003-05-12 | Baylor College Of Medicine | Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen |
US7294708B2 (en) * | 2002-05-31 | 2007-11-13 | Beijing Institute Of Biotechnology | Telomerase reverse transcriptase fragments and uses thereof |
EP1991560B1 (en) | 2006-02-20 | 2018-04-04 | Ewha University-Industry Collaboration Foundation | Peptide having cell membrane penetrating activity |
EP1994942A1 (en) * | 2007-05-25 | 2008-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions comprising telomerase, and uses thereof |
EP2310044B1 (en) * | 2008-06-16 | 2016-08-24 | Mediolanum Farmaceutici S.p.A. | Anti-tumor immunotherapy |
US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
KR101169030B1 (ko) | 2009-01-21 | 2012-07-26 | 애니젠 주식회사 | 신규한 세포막 투과 도메인 및 이를 포함하는 세포내 전달 시스템 |
JP5653214B2 (ja) | 2009-05-20 | 2015-01-14 | 東レ株式会社 | 細胞膜透過性ペプチド |
KR102035199B1 (ko) | 2010-02-16 | 2019-10-22 | 울티모백스 에이에스 | 폴리펩티드 |
KR101263212B1 (ko) | 2010-05-28 | 2013-05-10 | 성신여자대학교 산학협력단 | 신규한 세포막 투과성 펩타이드 및 그의 용도 |
CN108841802B (zh) | 2012-05-11 | 2023-06-09 | 珍白斯凯尔有限公司 | 抗炎性肽及包含其的组合物 |
KR101799904B1 (ko) | 2012-07-11 | 2017-11-22 | 주식회사 젬백스앤카엘 | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
CN113699133A (zh) | 2012-09-19 | 2021-11-26 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含其的缀合物、及应用 |
CN110092817B (zh) | 2012-09-19 | 2023-04-18 | 珍白斯凯尔有限公司 | 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物 |
KR101778244B1 (ko) | 2014-05-13 | 2017-09-26 | 한양대학교 산학협력단 | 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법 |
-
2013
- 2013-09-17 WO PCT/KR2013/008445 patent/WO2014046481A1/ko active Application Filing
- 2013-09-17 ES ES13839102T patent/ES2743919T3/es active Active
- 2013-09-17 TW TW102133733A patent/TWI598441B/zh active
- 2013-09-17 JP JP2015532965A patent/JP6510410B2/ja active Active
- 2013-09-17 CN CN201910048425.2A patent/CN110028554B/zh active Active
- 2013-09-17 US US14/429,641 patent/US9631184B2/en active Active
- 2013-09-17 CN CN201380057722.4A patent/CN104768967B/zh active Active
- 2013-09-17 KR KR1020157009510A patent/KR102201430B1/ko active IP Right Grant
- 2013-09-17 EP EP13839102.4A patent/EP2899199B1/en active Active
- 2013-09-17 CN CN201910049089.3A patent/CN110064056B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010252810A (ja) * | 1998-07-08 | 2010-11-11 | Gemvax As | テロメラーゼ由来抗原ペプチド |
US20090186802A1 (en) * | 2005-12-16 | 2009-07-23 | Diatos | Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell |
KR20090103957A (ko) * | 2007-01-29 | 2009-10-01 | 주식회사 프로셀제약 | 신규한 거대분자 전달 도메인 및 이의 동정 방법 및 용도 |
WO2010012850A1 (es) * | 2008-07-29 | 2010-02-04 | Universitat Pompeu Fabra | Péptidos con capacidad de penetración celular y sus usos |
WO2011150494A1 (en) * | 2010-05-30 | 2011-12-08 | The Governing Council Of The University Of Toronto | Mitochondrial penetrating peptides as carriers for anticancer compounds |
KR20120026408A (ko) * | 2010-09-09 | 2012-03-19 | 서울대학교산학협력단 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
Non-Patent Citations (10)
Title |
---|
FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 811 |
LOTTSPEICH, F.; ZORBAS H.: "Bioanalytik", 1998, SPEKTRUM AKADEMISCHER VERLAG |
LUFT R; IKKOS D; PALMIERI G; ERNSTER L; AFZELIUS B: "A case of severe hypermetabolism of non thyroid origin with a defect in the maintenance of mitochondrial respiratory control : a correlated clinical, biochemical, and morphological study", J CLIN INVEST, vol. 41, 1962, pages 1776 - 804 |
MODICA-NAPOLITANO KS; SINGH KK: "April mitochondria as targets for detection and treatment of cancer", EXPERT REV MOL MED, vol. 11, 2002, pages 1 - 19 |
NOVINA; SHARP, NATURE, vol. 430, 2004, pages 161 - 164 |
RANA, T. M., NAT. REV. MOL. CELL BIOL., vol. 8, 2007, pages 23 - 36 |
RANDAL J. KAUFMAN, CURRENT PROTOCOLS IN MOLYCULAR BIOLOGY, vol. 16, 1991, pages 12 |
See also references of EP2899199A4 |
SMITH ET AL., GENE, vol. 67, 1988, pages 31 - 40 |
TOMARI, Y.; ZAMORE, P. D., GENES DEV., vol. 19, 2005, pages 517 - 529 |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10960056B2 (en) | 2012-05-11 | 2021-03-30 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US11857607B2 (en) | 2012-05-11 | 2024-01-02 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US9730984B2 (en) | 2012-05-11 | 2017-08-15 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating rheumatoid arthritis |
US9844584B2 (en) | 2012-05-11 | 2017-12-19 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating sepsis |
US9907837B2 (en) | 2012-05-11 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition for preventing or treating cachexia |
US9540419B2 (en) | 2012-05-11 | 2017-01-10 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US11369665B2 (en) | 2012-05-11 | 2022-06-28 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US10039811B2 (en) | 2012-05-11 | 2018-08-07 | Gemvax & Kael Co., Ltd. | Anti-inflammatory peptides and composition comprising the same |
US10967000B2 (en) | 2012-07-11 | 2021-04-06 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide, conjugate comprising same and composition comprising same |
US9907838B2 (en) | 2013-04-19 | 2018-03-06 | Gemvax & Kael Co., Ltd. | Composition and methods for treating ischemic damage |
US10383926B2 (en) | 2013-06-07 | 2019-08-20 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
US10561703B2 (en) | 2013-06-21 | 2020-02-18 | Gemvax & Kael Co., Ltd. | Method of modulating sex hormone levels using a sex hormone secretion modulator |
EP3020724A4 (en) * | 2013-07-12 | 2017-01-18 | Gemvax & Kael Co., Ltd. | Cell-penetrating peptide and conjugate comprising same |
US10034922B2 (en) | 2013-11-22 | 2018-07-31 | Gemvax & Kael Co., Ltd. | Peptide having angiogenesis inhibitory activity and composition containing same |
US11058744B2 (en) | 2013-12-17 | 2021-07-13 | Gemvax & Kael Co., Ltd. | Composition for treating prostate cancer |
US9937240B2 (en) | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
US10463708B2 (en) | 2014-12-23 | 2019-11-05 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US11077163B2 (en) | 2014-12-23 | 2021-08-03 | Gemvax & Kael Co., Ltd. | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same |
US10835582B2 (en) | 2015-02-27 | 2020-11-17 | Gemvax & Kael Co. Ltd. | Peptide for preventing hearing loss, and composition comprising same |
US11015179B2 (en) | 2015-07-02 | 2021-05-25 | Gemvax & Kael Co., Ltd. | Peptide having anti-viral effect and composition containing same |
US10441632B2 (en) | 2016-01-29 | 2019-10-15 | Nexgen Biotechnologies, Inc. | Anti-wrinkle and anti-aging cosmetic composition comprising green fluorescent protein-human epidermal growth factor fusion protein as effective component |
US10898540B2 (en) | 2016-04-07 | 2021-01-26 | Gem Vax & KAEL Co., Ltd. | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same |
Also Published As
Publication number | Publication date |
---|---|
TW201416448A (zh) | 2014-05-01 |
CN110028554B (zh) | 2023-04-07 |
TWI598441B (zh) | 2017-09-11 |
CN104768967A (zh) | 2015-07-08 |
ES2743919T3 (es) | 2020-02-21 |
CN110064056A (zh) | 2019-07-30 |
JP6510410B2 (ja) | 2019-05-08 |
CN110028554A (zh) | 2019-07-19 |
US20160002613A1 (en) | 2016-01-07 |
US9631184B2 (en) | 2017-04-25 |
JP2015530404A (ja) | 2015-10-15 |
CN110064056B (zh) | 2022-10-28 |
KR102201430B1 (ko) | 2021-01-12 |
EP2899199B1 (en) | 2019-07-03 |
EP2899199A4 (en) | 2016-06-15 |
EP2899199A1 (en) | 2015-07-29 |
KR20150060763A (ko) | 2015-06-03 |
CN104768967B (zh) | 2019-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7007423B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
JP7041187B2 (ja) | 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物 | |
WO2014046481A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 | |
WO2014010971A1 (ko) | 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13839102 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015532965 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14429641 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20157009510 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013839102 Country of ref document: EP |